{
    "nct_id": "NCT05901545",
    "official_title": "Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer",
    "inclusion_criteria": "* Age ≥ 19 years.\n* Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck, clinically-staged as node-negative (cN0) or as clinically-suspicious node(s).\n* Subjects diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Subjects with recurrent disease or a new primary will be allowed.\n* Planned standard of care elective neck dissection for node-negative or node-positive disease.\n* Have acceptable hematologic status, kidney function, and liver function including the following clinical results:\n\n  * Hemoglobin ≥ 9 gm/dL\n  * White blood cell count > 3000/mm^3\n  * Platelet count ≥ 100,000/mm^3\n  * Serum creatinine ≤ 1.5 times upper reference range\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.\n* History of infusion reactions to monoclonal antibody therapies\n* History of allergies to iodine\n* Pregnant or breastfeeding.\n* Magnesium or potassium lower than the normal institutional values.\n* Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.\n* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.\n* Severe renal disease or anuria.",
    "miscellaneous_criteria": ""
}